Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CEA-loaded dendritic cell vaccine** is an investigational, autologous dendritic-cell cancer-vaccine intervention evaluated by Radboud University Medical Center in colorectal cancer. Patient-derived mature dendritic cells were loaded with the tumor-associated antigen carcinoembryonic antigen either by pulsing with a CEA peptide or by electroporation with CEA messenger RNA. The antigen-presenting cells are intended to prime and expand CEA-specific T-cell responses against CEA-expressing colorectal-cancer cells. The trial terminology encompasses more than one product preparation, rather than a single chemically defined drug with an INN. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00228189))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CEA-loaded dendritic cell vaccine.